To start a peptide therapy business online, you launch a telehealth brand around peptides that are lawful to prescribe and fill today. Licensed clinicians from a clinician network prescribe after an online visit, a licensed pharmacy fills each prescription, and your company owns the brand and its patients. In October 2026 that means FDA-approved peptide drugs, plus compounded peptides whose ingredient a 503A pharmacy may use. BPC-157, TB-500 and the other peptides FDA's advisory committee backed in July can't be compounded yet. thimblehub sets up and runs your checkout, intake, patient and admin portals and site on the clinician network and pharmacy you choose, and introduces both if you need them.
Telehealth clinicians can prescribe peptides. None of the peptides in this guide is a federally controlled substance, so DEA's telehealth rules don't apply, and each patient's state sets the licensing and visit rules. Many states limit who can own a medical practice, so have a healthcare attorney check your structure, your states and your menu before you sell. Our guide to starting a telehealth company covers the steps every category shares.
Where peptide rules stand on October 12, 2026
- The committee backed six. On July 23 and 24, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, semax and epitalon to the 503A bulks list, and voted against emideltide (DSIP). The tally for BPC-157, KPV and TB-500 was 8 to 6, with one abstention, as AJMC reported. FDA staff had proposed adding none of the seven.
- FDA hasn't acted. A committee vote is a recommendation. Adding a substance takes a proposed rule, public comment and a final rule, and none had appeared in the Federal Register by October 12. Until a final rule lists them, pharmacies can't lawfully compound these six.
- April's change was procedural. FDA took BPC-157, TB-500 and other peptides off its category 2 safety-risk list after their nominators withdrew them. That left them in no category, so the interim policy covering category 1 ingredients doesn't reach them.
- More reviews ahead. FDA plans to consult the committee on GHK-Cu before the end of February 2027.
Which peptides you can offer in 2026
A 503A pharmacy may compound with a bulk ingredient only if it meets a USP monograph, is part of an FDA-approved drug, or is on FDA's 503A bulks list. While FDA works through nominations, it also says it won't act against pharmacies using ingredients in its category 1. Every compounded prescription is for one patient.
| Group | Can a pharmacy fill it today? | Examples | What your program needs |
|---|---|---|---|
| FDA-approved peptide drugs | Yes, as the approved product | Semaglutide (Wegovy), tirzepatide (Zepbound), tesamorelin (Egrifta WR), bremelanotide (Vyleesi) | A prescription and any licensed pharmacy. Claims stay within each drug's label. |
| Ingredients of approved drugs, compounded | Yes, from a 503A pharmacy, one patient at a time | Bremelanotide (PT-141), sermorelin acetate | A prescription per patient. Regular copies of a drug that's still sold are off limits. |
| Category 1, still under FDA review | Yes, from a 503A pharmacy, while FDA decides | Glutathione, GHK-Cu for non-injectable use, vasoactive intestinal peptide | An ingredient from an FDA-registered maker with a certificate of analysis |
| Backed by FDA's committee, awaiting a rule | No | BPC-157, KPV, TB-500, MOTS-c, semax, epitalon | A final FDA rule adding them to the 503A bulks list |
| Category 2, safety risks | No | Kisspeptin-10, ibutamoren (MK-677, a non-peptide) | FDA would have to clear the safety risks it found |
| Withdrawn, rejected or category 3 | No | CJC-1295, ipamorelin, AOD-9604, thymosin alpha-1, selank, melanotan II, emideltide, GHRP-6 | A nomination, FDA review and a final rule |
Sources: FDA's 503A category lists (updated May 14, 2026), its category 2 page (updated April 22, 2026), its briefing document for the July 23 and 24, 2026 committee meeting, its 503B category list (updated March 21, 2025), DailyMed labels for Egrifta WR and Vyleesi, and 21 U.S.C. 353a. Checked October 12, 2026.
Compounding from an approved drug's ingredient has two limits. A 503A pharmacy can't regularly make what is essentially a copy of a drug that's still sold, unless the prescriber documents a change that makes a significant difference for that patient. And a peptide longer than 40 amino acids counts as a protein, which FDA licenses as a biologic, and biologics can't be compounded under 503A or 503B. Tesamorelin is one: Egrifta WR holds a biologics license. Our GLP-1 guide shows how the copy limit works for semaglutide and tirzepatide.
503B outsourcing facilities register with FDA, follow manufacturing quality rules (CGMP) and can make batches without a prescription for each patient. They may use a bulk ingredient only if it's on FDA's 503B bulks list, which holds five substances and no peptides, or if the drug is in shortage. Under FDA's interim policy, they may also use ingredients in 503B category 1, which includes sermorelin acetate, gonadorelin acetate and glutathione. None of the July seven appears on FDA's 503B lists. Only the facility that made a drug may sell or transfer it. That rule doesn't bar dispensing it on a prescription or giving it in a health care setting. Our compounding pharmacy guide compares 503A and 503B partners.
Steps to launch, and who does each
thimblehubYour menu, checked by an attorney
You pick your menu from the table above and walk a healthcare attorney through it: your company structure, your launch states, and what your site and ads will say.
A clinician network
You bring your clinician network, or we introduce one we work with and you agree terms directly. Networks we work with include MDI, OpenLoop, Beluga, Wizlo and Arora, and we connect any other network during setup. The network decides which peptides its clinicians will prescribe.
A licensed pharmacy
You use your network's pharmacy or one you contract, or we introduce one. Compounded peptides go to a 503A pharmacy licensed to ship to your patients' states, or a 503B facility for ingredients on its lists.
The clinical protocol
Your network's clinicians set the protocol: who qualifies, what rules a patient out, dosing and any labs. We shape your intake around it and set up lab testing with at-home kits, walk-in draws or mobile phlebotomy.
Your brand, set up and connected
thimblehub sets up your site, checkout and intake, and patient and admin portals on your brand, your domain and your own payment processor, such as Stripe. Then we connect your network and pharmacy and start routing orders to them.
LegitScript certification
You apply for LegitScript certification before you run paid ads. Your site is built to LegitScript's requirements, and we support your application.
A test order, together
You and our team run a test order together, through every step a patient takes, before you go live.
Comparing networks? Our clinician networks guide lays out how they differ, and our integrations page shows how we set up any network and pharmacy you choose.
What to keep off your menu, site and ads
- Peptides FDA hasn't cleared for compounding. BPC-157 and the other July six wait on a final rule. Kisspeptin-10 sits in category 2, FDA's safety-risk list.
- Peptides from outside a pharmacy. Your patients get peptides only through prescriptions a licensed pharmacy fills, and a 503A pharmacy's bulk ingredients must come from an FDA-registered maker with a valid certificate of analysis. On August 27, 2026, FDA also told compounders not to use dietary supplement grade glutathione in injectables after at least 30 patients had adverse events.
- Growth hormone for anti-aging. Federal law makes distributing human growth hormone for a use FDA hasn't approved a crime punishable by up to 5 years in prison.
- Outcome claims. The FTC expects health claims to rest on competent and reliable scientific evidence, generally randomized, controlled human trials. RAPS reported that FDA staff cited a lack of evidence for BPC-157's effectiveness.
- Ads before certification. Google and Meta both require LegitScript certification for telehealth advertisers, then their own approval. LegitScript said on July 27, 2026 that the committee's recommendations don't change its certification standards.
Our LegitScript guide walks through certification, our Meta ads guide covers tracking once you're approved, and our longevity guide covers programs such as rapamycin and NAD+.
What we set up for peptide brands
thimblehub is fully managed. We set up and run your checkout, intake, patient and admin portals and brand site for the peptide programs your clinicians and counsel clear: FDA-approved peptide drugs, and compounded peptides a pharmacy may lawfully make.
- Menu changes when rules move. When FDA changes a peptide's status and your counsel clears the change, we update your menu, intake and checkout for you.
- Refill check-ins. Before each refill, patients answer a short check-in in their portal. You choose whether it's required, optional or off.
- Renewals. When a prescription runs out of refills, the renewal goes back to your clinician network with the check-in attached. The prescriber makes the call.
- A save flow. When a patient goes to cancel, the portal asks why and offers a pause or a skipped month.
More in how refills work on thimblehub.
See a longevity brand's checkout and portal
Open the demo set to longevity, type your brand name, and click through the checkout, intake and patient portal your patients would use.
Open the longevity demoHow long a peptide launch takes
| Where you are when you sign | When you can go live | What we do |
|---|---|---|
| Clinician network and pharmacy in place | As fast as 3 days after you sign | Set up your site, checkout, intake and portals, connect your network and pharmacy, and run a test order with you |
| No clinicians or pharmacy yet | Longer. Setup finishes once your terms are signed. | Introduce networks and pharmacies we work with. You agree terms with them directly. |
| Waiting on LegitScript certification for paid ads | When your certification and marketing are ready. A recent brand went live the morning after. | Support your certification with site changes, reviewer access and answers |
| Design revisions, marketing with us, or custom builds | Each adds time | Scope the work with you on the first call |
Launch times count from your signed contract.
Our onboarding guide walks through what happens after you sign.
What one call to thimblehub gets you
Tell us which peptides you want to offer and what you already have. One call covers the rest:
- Your site, checkout and intake, and patient and admin portals, set up and run by us on your brand and your domain.
- Your clinician network and pharmacy connected, or introductions to ones we work with.
- A flag on any peptide on your list that FDA hasn't cleared for compounding, and the name of a healthcare attorney we trust.
- Ad tracking set up with your site, and campaigns run for you if you want them, as an added engagement.
- Your patients, data, domain and payment processor stay yours, and every customer gets a signed BAA.
Frequently asked questions
- Can telehealth providers prescribe peptides?
- Yes. A clinician licensed in the patient's state can prescribe FDA-approved peptide drugs, and compounded peptides a pharmacy may lawfully make, after an online visit that meets that state's rules. None of the peptides in this guide is a federally controlled substance, so DEA's telehealth rules don't apply. thimblehub sets up and runs your peptide telehealth brand, fully managed: checkout and intake, patient and admin portals and your brand site, on the clinician network and pharmacy you choose or ones we introduce.
- Is BPC-157 legal to prescribe in 2026?
- Not in a way a pharmacy can lawfully fill today. BPC-157 has no FDA approval and no USP monograph, isn't part of an approved drug and isn't on FDA's 503A bulks list. FDA's advisory committee voted 8 to 6, with one abstention, on July 23, 2026 to recommend adding it. FDA makes the decision through a proposed rule, public comment and a final rule, and had published no proposed rule as of October 12, 2026. thimblehub sets up peptide brands around what pharmacies can lawfully fill today, and adds BPC-157 to your menu, intake and checkout if FDA lists it and your counsel clears it.
- Which peptides can a telehealth brand sell in 2026?
- FDA-approved peptide drugs such as semaglutide, tirzepatide, tesamorelin and bremelanotide, each prescribed by a licensed clinician. A 503A pharmacy can also compound with ingredients of approved drugs, such as bremelanotide and sermorelin acetate, within FDA's limits on copies. It may also use category 1 ingredients, such as glutathione and non-injectable GHK-Cu, while FDA reviews them.
- What's the difference between a 503A pharmacy and a 503B facility for peptides?
- A 503A pharmacy compounds for one patient on a prescription, overseen by its state board. A 503B outsourcing facility registers with FDA, follows manufacturing quality rules and can make batches. Its bulk ingredients must be on FDA's 503B bulks list or be for a drug in shortage, and under FDA's interim policy it may also use 503B category 1 ingredients such as sermorelin acetate. Neither may compound BPC-157 today.
- How fast can I launch a peptide telehealth brand?
- With thimblehub, as fast as 3 days after you sign. It takes longer if you still need a pharmacy or clinicians, are waiting on LegitScript certification, want website design revisions, are planning marketing with us, or need custom builds. A recent brand went live the morning after its LegitScript certification and marketing were ready.
- Can I run Meta or Google ads for a peptide brand?
- Yes, for peptides you can lawfully sell, once your brand holds LegitScript certification and each platform approves you. LegitScript said on July 27, 2026 that the committee's July recommendations don't change its certification standards.
Questions, or a topic you'd like us to cover? Book a call or email hello@thimblehub.com.
Sources
- FDA: Bulk drug substances used in compounding under section 503A (updated May 14, 2026)
- FDA: Bulk drug substances nominated under section 503A, categories 1 to 3 (updated May 14, 2026)
- FDA: Bulk drug substances that may present significant safety risks, category 2 (updated Apr 22, 2026)
- FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee
- FDA: Briefing document for the July 23-24, 2026 committee meeting
- Federal Register: Committee meeting notice and the seven peptides under review, 91 FR 20465 (Apr 16, 2026)
- RAPS: FDA advisory committee backs two controversial peptides (Jul 23, 2026)
- AJMC: FDA panel backs 6 peptides for compounding (Jul 31, 2026)
- Latham & Watkins: FDA on peptides (Aug 6, 2026)
- LegitScript: What the July 2026 FDA advisory committee meetings on compounded peptides mean (Jul 27, 2026)
- FDA: Bulk drug substances nominated under section 503B, categories 1 to 3 (updated Mar 21, 2025)
- FDA: Information for outsourcing facilities
- FDA: 503B bulk drug substances list
- FDA: Compounders should not use dietary supplement grade glutathione for injectables (Aug 27, 2026)
- 21 U.S.C. 353a, pharmacy compounding (section 503A)
- 21 U.S.C. 353b, outsourcing facilities (section 503B)
- 21 U.S.C. 333(e), human growth hormone
- DEA: Controlled substances in alphabetical order (Aug 2026)
- FDA: Notice to compounders on biological products (Mar 2020)
- 21 CFR 600.3(h)(6), definition of a protein
- DailyMed: Egrifta WR (tesamorelin) label
- DailyMed: Vyleesi (bremelanotide) label
- FTC: Health products compliance guidance
- Google Ads policy: Healthcare and medicines
- Meta: Drugs and pharmaceuticals ad standard